Literature DB >> 30291433

[Pathogenesis of systemic lupus erythematosus].

S Finzel1, S Schaffer1, M Rizzi1, R E Voll2.   

Abstract

The causes of diseases and disorders of the immune system, which lead to the development of systemic lupus erythematosus (SLE), are not yet completely understood; however, it is known that there are various mechanisms, which can lead to SLE. The development of the disease is based on an underlying genetic disposition but is first triggered by exposure to environmental factors, such as sunburn, viral infections or vitamin D deficiency. Disease flares can also be triggered by environmental factors. Many disease manifestations are caused by pathogenic autoantibodies; hence, B‑cells and plasma cells play a critical role in the pathogenesis of SLE. This review provides an overview of the most frequent factors leading to the development of SLE and describes the key mechanisms of its pathogenesis.

Entities:  

Keywords:  Autoantibodies; B-cells; Environmental factors; Genetic predisposition; Immune complex disease

Mesh:

Substances:

Year:  2018        PMID: 30291433     DOI: 10.1007/s00393-018-0541-3

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  52 in total

1.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Authors:  Gabor G Illei; Yuko Shirota; Cheryl H Yarboro; Jimmy Daruwalla; Edward Tackey; Kazuki Takada; Thomas Fleisher; James E Balow; Peter E Lipsky
Journal:  Arthritis Rheum       Date:  2010-02

2.  A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab.

Authors:  Y Satoh; K Nakano; H Yoshinari; S Nakayamada; S Iwata; S Kubo; I Miyagawa; M Yoshikawa; Y Miyazaki; K Saito; Y Tanaka
Journal:  Lupus       Date:  2018-03-09       Impact factor: 2.911

3.  OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response.

Authors:  Clément Jacquemin; Nathalie Schmitt; Cécile Contin-Bordes; Yang Liu; Priya Narayanan; Julien Seneschal; Typhanie Maurouard; David Dougall; Emily Spence Davizon; Hélène Dumortier; Isabelle Douchet; Loïc Raffray; Christophe Richez; Estibaliz Lazaro; Pierre Duffau; Marie-Elise Truchetet; Liliane Khoryati; Patrick Mercié; Lionel Couzi; Pierre Merville; Thierry Schaeverbeke; Jean-François Viallard; Jean-Luc Pellegrin; Jean-François Moreau; Sylviane Muller; Sandy Zurawski; Robert L Coffman; Virginia Pascual; Hideki Ueno; Patrick Blanco
Journal:  Immunity       Date:  2015-06-09       Impact factor: 31.745

4.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

5.  Experimental lupus is aggravated in mouse strains with impaired induction of neutrophil extracellular traps.

Authors:  Deborah Kienhöfer; Jonas Hahn; Julia Stoof; Janka Zsófia Csepregi; Christiane Reinwald; Vilma Urbonaviciute; Caroline Johnsson; Christian Maueröder; Malgorzata J Podolska; Mona H Biermann; Moritz Leppkes; Thomas Harrer; Malin Hultqvist; Peter Olofsson; Luis E Munoz; Attila Mocsai; Martin Herrmann; Georg Schett; Rikard Holmdahl; Markus H Hoffmann
Journal:  JCI Insight       Date:  2017-05-18

6.  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX.

Authors:  Geoffrey Hom; Robert R Graham; Barmak Modrek; Kimberly E Taylor; Ward Ortmann; Sophie Garnier; Annette T Lee; Sharon A Chung; Ricardo C Ferreira; P V Krishna Pant; Dennis G Ballinger; Roman Kosoy; F Yesim Demirci; M Ilyas Kamboh; Amy H Kao; Chao Tian; Iva Gunnarsson; Anders A Bengtsson; Solbritt Rantapää-Dahlqvist; Michelle Petri; Susan Manzi; Michael F Seldin; Lars Rönnblom; Ann-Christine Syvänen; Lindsey A Criswell; Peter K Gregersen; Timothy W Behrens
Journal:  N Engl J Med       Date:  2008-01-20       Impact factor: 91.245

Review 7.  The genetics of type I interferon in systemic lupus erythematosus.

Authors:  Paola G Bronson; Christina Chaivorapol; Ward Ortmann; Timothy W Behrens; Robert R Graham
Journal:  Curr Opin Immunol       Date:  2012-08-10       Impact factor: 7.486

8.  Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.

Authors:  Daniel J Wallace; Richard A Furie; Yoshiya Tanaka; Kenneth C Kalunian; Marta Mosca; Michelle A Petri; Thomas Dörner; Mario H Cardiel; Ian N Bruce; Elisa Gomez; Tara Carmack; Amy M DeLozier; Jonathan M Janes; Matthew D Linnik; Stephanie de Bono; Maria E Silk; Robert W Hoffman
Journal:  Lancet       Date:  2018-07-21       Impact factor: 79.321

9.  Smoking and the risk of systemic lupus erythematosus.

Authors:  Susanne Ekblom-Kullberg; Hannu Kautiainen; Pirkko Alha; Marjatta Leirisalo-Repo; Heikki Julkunen
Journal:  Clin Rheumatol       Date:  2013-03-21       Impact factor: 2.980

10.  Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus.

Authors:  M Herrmann; R E Voll; O M Zoller; M Hagenhofer; B B Ponner; J R Kalden
Journal:  Arthritis Rheum       Date:  1998-07
View more
  4 in total

1.  Seluang Fish (Rasbora Spp.) Oil Decreases Inflammatory Cytokines Via Increasing Vitamin D Level in Systemic Lupus Erythematosus.

Authors:  Radiyati Umi Partan; Rachmat Hidayat; Nurwan Saputra; Febry Rahmayani; Hari Prapto; Timotius Wira Yudha
Journal:  Open Access Maced J Med Sci       Date:  2019-05-05

2.  Systematic review and meta-analysis of clinical outcomes comparison between different initial dialysis modalities in end-stage renal disease patients due to lupus nephritis prior to renal transplantation.

Authors:  Joel Swai; Xiexiong Zhao; Julie-Raisa Noube; Gui Ming
Journal:  BMC Nephrol       Date:  2020-05-01       Impact factor: 2.388

3.  Longitudinal DNA methylation dynamics as a practical indicator in clinical epigenetics.

Authors:  Shohei Komaki; Hideki Ohmomo; Tsuyoshi Hachiya; Yoichi Sutoh; Kanako Ono; Ryohei Furukawa; So Umekage; Yayoi Otsuka-Yamasaki; Kozo Tanno; Makoto Sasaki; Atsushi Shimizu
Journal:  Clin Epigenetics       Date:  2021-12-13       Impact factor: 6.551

Review 4.  Interleukin-35 in autoimmune dermatoses: Current concepts.

Authors:  Yuming Xie; Huilin Zhang; Junke Huang; Qing Zhang
Journal:  Open Med (Wars)       Date:  2022-03-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.